Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Diabetes

Fenofibrate works in women as well as men

Diabetes testing for glucose levels

Source: istockphoto.com

Women with diabetes can benefit from fenofibrate therapy, say researchers

In 2010, results from the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial[1] suggested a gender disparity in the effectiveness of fenofibrate treatment in type 2 diabetes, with a subgroup analysis signalling possible harm in women.

This is challenged by latest results from the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study, reported in Diabetologia (online, 18 August 2014)[2]. A pre-specified analysis found that cardiovascular event reductions with fenofibrate are consistently similar in women and men and that fenofibrate improves the lipoprotein profile more in women than men.

“These data provide reassurance about fenofibrate efficacy in women and men,” write the FIELD researchers, led by Anthony Keech, from the University of Sydney, Australia. “Both sexes with type 2 diabetes should be considered for fenofibrate therapy for cardioprotection.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066240

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Diabetes testing for glucose levels

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.